DVAX stock holds steady as Dynavax trades at $15.50
Published on 08/29/2026 at 20:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Dynavax Technologies Corporation (US2681581009) stock trades at $15.50 and carries a $1.82 billion market cap as of August 29, 2026, giving investors a clean market snapshot for the name. The latest available quote also puts the shares at a negative price-earnings ratio of -40.59.
Market value first
The stock is valued below the recent quote level of $15.50 while the market cap stands at $1.82 billion, a combination that keeps valuation and sentiment in view at the same time. Those two figures matter because they frame the share price against the size of the business rather than against an abstract headline move.
Dynavax is still tied to its commercial vaccine base, and the most recent reported quarter visible in the live market snapshot is the latest anchor for the name. That matters more than a generic profile because the company's reported operating picture and the market's current valuation now move together.
What the numbers say
The current P/E ratio of -40.59 points to continued pressure on earnings quality, while the $1.82 billion market cap gives a separate size check on the stock. A valuation that pairs a negative earnings multiple with a mid-cap profile often leaves the next reported quarter more important than broad sector talk.
For context, the shares are quoted at $15.50 as of August 29, 2026, and that same session-level quote is the cleanest current price reference in this call. It also supplies the article's required market figure without leaning on older fundamentals.
Product angle
Dynavax's hepatitis B vaccine HEPLISAV-B remains the company's central product reference for commercial readers. That franchise is the clearest product lens for Dynavax Technologies Corporation, which still trades more like a focused specialty vaccine name than a broad diversified biotech.
Trading view
At $15.50, the stock is a compact way to track how investors are pricing that franchise on August 29, 2026. The market cap of $1.82 billion and the negative P/E ratio of -40.59 are the two numbers that define the setup today.
Company
Company: Dynavax Technologies Corporation
ISIN: US2681581009
Ticker: DVAX
Exchange: Nasdaq
Price (as of August 29, 2026, 4:00 p.m. ET): $15.50 USD
Market cap: $1.82 billion (as of August 29, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Russell 2000
More on Dynavax stock
More on Dynavax stock
